Dermapharm Holding Se · XETR:DMP

Dermapharm — Q1 2018 Earnings Presentation

21 slides from Dermapharm's earnings presentation, May 18, 2018

  1. Slide 1: Investors and Analysts Conference Call Q1 2018

    Investors and Analysts Conference Call Q1 2018 Grünwald, 18 May 2018

  2. Slide 2: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Stat

  3. Slide 3: Today's agenda

    Today’s agenda 1. Overview 2. Financial figures Q1 2018 3. Outlook FY 2018 3

  4. Slide 4: Overview

    Overview Section 1

  5. Slide 5: Dermapharm – The Management Team

    1. Overview Dermapharm – The Management Team Dr. Hans Feldmeier Karin Samusch Stefan Grieving Stefan Hümer CEO CBDO CMO CFO 5

  6. Slide 6: Highlights Q1 2018 – Success story with profitable growth continued

    1. Overview Highlights Q1 2018 – Success story with profitable growth continued Significant revenue growth Revenues increased by 16.4% to € 137.5 million Disproportionate EBITDA growth Adjusted EBITDA¹ increased by 25.3% to € 36.2 m; adjusted EBITDA¹ margin up to 26.3% Significant growth impulses fr

  7. Slide 7: Financial figures Q1 2018

    Financial figures Q1 2018 Section 2

  8. Slide 8: Dermapharm Group Revenue – Driven by significant growth in Branded Pharmaceuticals

    2. Financial figures Q1 2018 Dermapharm Group Revenue – Driven by significant growth in Branded Pharmaceuticals segments Dermapharm’s revenue development Dermapharm Group Q1 2017 vs Q1 2018 €m, YoY growth (%)  Strong revenue growth of 16.4% to € 137.5 million  Main growth drivers:  Successful com

  9. Slide 9: Dermapharm Group EBITDA – Disproportional EBITDA growth, with margin improvement

    2. Financial figures Q1 2018 Dermapharm Group EBITDA – Disproportional EBITDA growth, with margin improvement Dermapharm’s EBITDA development Dermapharm Group Q1 2017 vs Q1 2018 €m, YoY growth (%)  EBITDA growth driven by Branded Pharmaceuticals EBITDA  One-time costs of € 0.7 million for IPO prep

  10. Slide 10: Earnings before tax (EBT) – Reflecting company's high profitability

    2. Financial figures Q1 2018 Earnings before tax (EBT) – Reflecting company’s high profitability, with margin improvement Dermapharm’s EBT development Comments Q1 2017 vs Q1 2018 €m, YoY growth (%)  EBT increased by 23.6% to € 29.9 million (adjusted) resulting in a margin of 21.7%  EBT of € 29.2 m

  11. Slide 11: Strong Cash flows and cash conversion

    2. Financial figures Q1 2018 Strong Cash flows and cash conversion – Reflecting strong dedication to future growth Cash flows Comments Q1 2017 vs. Q1 2018, €m Cash conversion defined as CF from operating activities/EBITDA in %  CF from operating activities up due to positive business development Ca

  12. Slide 12: Balance sheet of Dermapharm Group

    2. Financial figures Q1 2018 Balance sheet of Dermapharm Group Balance Sheet 31 March 2018 Comments in €m  Total assets increased to € 679 million  Non-current assets increased mainly due to the increase of 679 679 Goodwill and other intangible assets Equity  Current assets increased mainly due t

  13. Slide 13: Outlook FY 2018

    Outlook FY 2018 Section 3

  14. Slide 14: Dermapharm follows a consequent portfolio strategy

    3. Outlook FY 2018 Dermapharm follows a consequent portfolio strategy Revenue by market access excl. axicorp(2) Comments  Acquisitions of Trommsdorff, Strathmann, Bio-Diät-Berlin and the hyperthermic devices further strengthen portfolio shift in Q1 2018 14%  Portfolio shift overall leads to 21% 29

  15. Slide 15: Growth strategy – Update on in-house development

    3. Outlook FY 2018 I Growth strategy – Update on in-house development Events Q1 2018 Plans 2018  All ongoing development projects on track  Target: Overall 70 new marketing authorizations, thereof  Several new products launched in different countries 15 in Germany  Germany: Myopridin®, Summavit®

  16. Slide 16: Growth strategy – Update on internationalization

    3. Outlook FY 2018 II Growth strategy – Update on internationalization Events Q1 2018 Plans 2018  Subsidiary established in Italy (Feb 2018)  Product roll-out in Italy and the UK and subsidiary foundation in Spain  Further internationalization of DermaTec hyperthermic medical devices  Obtain mar

  17. Slide 17: Growth strategy – Update on M&A activities

    3. Outlook FY 2018 III Growth strategy – Update on M&A activities Events Q1 2018 Plans 2018  01/2018: Acquisition of Strathmann and Trommsdorff  Integration of Bio-Diät-Berlin, Strathmann and  Due to purchase price adjustment clauses, reduction of Trommsdorff: purchase price for Trommsdorff; reim

  18. Slide 18: Business update axicorp Group

    3. Outlook FY 2018 Business update axicorp Group Events Q1 2018 Plans 2018  Sale of bite away® via call center started  Finalization of the falsification guideline project  Optimization of the portfolio towards high-margin  Sale of bite away® to 6,500 pharmacies via call center products  Ongoin

  19. Slide 19: Growth strategy on track confirming guidance 2018

    3. Outlook FY 2018 Growth strategy on track confirming guidance 2018 Revenues 2018 +20% to +25% over the previous year (2017: € 467 million) EBITDA 2018 (adjusted) +22% to +27% over the previous year (2017: € 113 million (adjusted)) Growth rates based on organic growth and the four acquisitions 2017

  20. Slide 20: Investor contact

    Investor contact Dr. Hans-Georg Feldmeier (CEO) Stefan Hümer (CFO) Karin Samusch (CBDO) Stefan Grieving (CMO) E-Mail: ir@dermapharm.de Phone: +49 (0) 89 64186 - 0 20

  21. Slide 21: Becoming the leading European pharmaceutical manufacturer in selected markets

    Becoming the leading European pharmaceutical manufacturer in selected markets

Dermapharm Holding — Q1 2018 Earnings Presentation on 6ix